Literature DB >> 20339887

A quantitative study of the biotransformation of insulin-enhancing VO(2+) compounds.

Daniele Sanna1, Péter Buglyó, Giovanni Micera, Eugenio Garribba.   

Abstract

Potentiometric (pH titrations) and spectroscopic (electron paramagnetic resonance) methods have been used to determine the thermodynamic stability constants of the various VO(2+) complexes formed after the interaction of four insulin-enhancing vanadium compounds, [VO(6-mepic)(2)], cis-[VO(pic)(2)(H(2)O)], [VO(acac)(2)], and [VO(dhp)(2)], where 6-mepic, pic, acac, and dhp indicate the deprotonated forms of 6-methylpicolinic acid, picolinic acid, acetylacetone, and 1,2-dimethyl-3-hydroxy-4(1H)-pyridinone, with high molecular mass [human serum apotransferrin (hTf) and human serum albumin (HSA)] and low molecular mass (lactate) components of blood serum. In particular, log beta values for the formation of (VO)hTf (13.0 +/- 0.5), (VO)(2)hTf (25.5 +/- 0.5), (VO)HSA (9.1 +/- 1.0), (VO) (2) (d) HSA (20.9 +/- 1.0), cis-VO(dhp)(2)(hTf) (25.5 +/- 0.6), cis-VO(dhp)(2)(HSA) (25.9 +/- 0.6), (VO)hTf(lact) (14.5 +/- 0.8), (VO)(2)hTf(lact)(2) (28.5 +/- 0.8), (VO)hTf(pic) (15.6 +/- 0.8), and (VO)(2)hTf(pic)(2) (30.4 +/- 0.8) were determined. The values of the stability constants were used to compare the calculated composition of ternary and quinary systems with that recently proposed by some of us through electron paramagnetic resonance and density functional theory methods (Sanna et al. in Inorg. Chem. 49:174-187, 2010) and to predict the distribution of VO(2+) ion in blood serum when one of the four insulin-enhancing vanadium compounds studied, [VO(carrier)(2)], is administered.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20339887     DOI: 10.1007/s00775-010-0647-9

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  34 in total

Review 1.  The chemistry and biochemistry of vanadium and the biological activities exerted by vanadium compounds.

Authors:  Debbie C Crans; Jason J Smee; Ernestas Gaidamauskas; Luqin Yang
Journal:  Chem Rev       Date:  2004-02       Impact factor: 60.622

2.  New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.

Authors:  Barry D Liboiron; Katherine H Thompson; Graeme R Hanson; Edmond Lam; Nicolas Aebischer; Chris Orvig
Journal:  J Am Chem Soc       Date:  2005-04-13       Impact factor: 15.419

3.  Possible mode of action for insulinomimetic activity of vanadyl(IV) compounds in adipocytes.

Authors:  Kenji Kawabe; Yutaka Yoshikawa; Yusuke Adachi; Hiromu Sakurai
Journal:  Life Sci       Date:  2005-12-06       Impact factor: 5.037

Review 4.  Speciation of insulin-mimetic VO(IV)-containing drugs in blood serum.

Authors:  T Kiss; E Kiss; E Garribba; H Sakurai
Journal:  J Inorg Biochem       Date:  2000-05-30       Impact factor: 4.155

5.  In vitro study of the insulin-mimetic behaviour of vanadium(IV, V) coordination compounds.

Authors:  Dieter Rehder; João Costa Pessoa; Carlos F G C Geraldes; MargaridaM C A Castro; Themistoklis Kabanos; Tamás Kiss; Beate Meier; Giovanni Micera; Lage Pettersson; Maria Rangel; Athanasios Salifoglou; Iztok Turel; Dongren Wang
Journal:  J Biol Inorg Chem       Date:  2001-12-19       Impact factor: 3.358

6.  Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.

Authors:  Abdol-Khalegh Bordbar; A Louise Creagh; Fakhrossadat Mohammadi; Charles A Haynes; Chris Orvig
Journal:  J Inorg Biochem       Date:  2008-10-17       Impact factor: 4.155

7.  Arene control over thiolate to sulfinate oxidation in albumin by organometallic ruthenium anticancer complexes.

Authors:  Wenbing Hu; Qun Luo; Xiaoyan Ma; Kui Wu; Jianan Liu; Yi Chen; Shaoxiang Xiong; Jianping Wang; Peter J Sadler; Fuyi Wang
Journal:  Chemistry       Date:  2009-07-06       Impact factor: 5.236

8.  Orally active and long-term acting insulin-mimetic vanadyl complex:bis(picolinato)oxovanadium (IV).

Authors:  H Sakurai; K Fujii; H Watanabe; H Tamura
Journal:  Biochem Biophys Res Commun       Date:  1995-09-25       Impact factor: 3.575

9.  Electronic structure of oxovanadium IV complexes of alpha-hydroxycarboxylic acids.

Authors:  Eugenio Garribba; Giovanni Micera; Angelo Panzanelli; Daniele Sanna
Journal:  Inorg Chem       Date:  2003-06-30       Impact factor: 5.165

Review 10.  Vanadium treatment of type 2 diabetes: a view to the future.

Authors:  Katherine H Thompson; Jay Lichter; Carl LeBel; Michael C Scaife; John H McNeill; Chris Orvig
Journal:  J Inorg Biochem       Date:  2008-12-24       Impact factor: 4.155

View more
  7 in total

1.  Vanadyl bisacetylacetonate protects β cells from palmitate-induced cell death through the unfolded protein response pathway.

Authors:  Zhonglan Gao; Chengyue Zhang; Siwang Yu; Xiaoda Yang; Kui Wang
Journal:  J Biol Inorg Chem       Date:  2011-04-22       Impact factor: 3.358

2.  Application of DFT methods to the study of the coordination environment of the VO2+ ion in V proteins.

Authors:  Daniele Sanna; Vincent L Pecoraro; Giovanni Micera; Eugenio Garribba
Journal:  J Biol Inorg Chem       Date:  2012-04-15       Impact factor: 3.358

3.  Binding of V(IV)O²⁺ to the Fe binding sites of human serum transferrin. A theoretical study.

Authors:  Gonçalo C Justino; Eugenio Garribba; João Costa Pessoa
Journal:  J Biol Inorg Chem       Date:  2013-10       Impact factor: 3.358

4.  Multiple and Variable Binding of Pharmacologically Active Bis(maltolato)oxidovanadium(IV) to Lysozyme.

Authors:  Giarita Ferraro; Maddalena Paolillo; Giuseppe Sciortino; Eugenio Garribba; Antonello Merlino
Journal:  Inorg Chem       Date:  2022-10-07       Impact factor: 5.436

5.  Coordination chemistry may explain pharmacokinetics and clinical response of vanadyl sulfate in type 2 diabetic patients.

Authors:  Gail R Willsky; Katherine Halvorsen; Michael E Godzala; Lai-Har Chi; Mathew J Most; Peter Kaszynski; Debbie C Crans; Allison B Goldfine; Paul J Kostyniak
Journal:  Metallomics       Date:  2013-11       Impact factor: 4.526

6.  ESI-MS Study of the Interaction of Potential Oxidovanadium(IV) Drugs and Amavadin with Model Proteins.

Authors:  Valeria Ugone; Daniele Sanna; Giuseppe Sciortino; Debbie C Crans; Eugenio Garribba
Journal:  Inorg Chem       Date:  2020-06-25       Impact factor: 5.165

Review 7.  Vanadium. Its role for humans.

Authors:  Dieter Rehder
Journal:  Met Ions Life Sci       Date:  2013
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.